William Blair on Sage Therapeutics (SAGE): 'we have difficulty envisioning what additional data could be generated to support a resubmission'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to William Blair on Sage Therapeutics (SAGE): 'we have difficulty envisioning what additional data could be generated to support a resubmission'

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

April 17, 2024 6:30 AM EDT

- In the Phase 2 PRECEDENT Study, dalzanemdor (SAGE-718) did not show statistically significant differences versus placebo on the primary endpoint in patients with mild cognitive impairment in Parkinsons disease

- Dalzanemdor (SAGE-718) was generally well-tolerated and there were no new safety signals observed

- Topline data readouts from the Phase 2 studies in Huntingtons disease and Alzheimers disease are expected later this year

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the... More